3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Recruiting
4
Completed
2
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Genitourinary
3
Tumor-Agnostic
1
Conditions
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Neoplasms
1
Interventions
Specimen Handling
302
Magnetic Resonance Spectroscopy
261
pembrolizumab
249
Carboplatin
184
Cyclophosphamide
175
Biopsy
167
Cisplatin
157
Gemcitabine
134
Paclitaxel
130
Bevacizumab
123
fludarabine
115
Nivolumab
108
Radiotherapy
107
Oxaliplatin
88
Docetaxel
87
Fluorouracil
85
Capecitabine
83
venetoclax
78
Dexamethasone
76
Pemetrexed
72
Rituximab
69
Leucovorin
69
Drug Therapy
69
atezolizumab
67
durvalumab
66
Radiosurgery
65
Blood Specimen Collection
64
Doxorubicin
63
Standard of Care
62
Radiation
61
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Recruiting
×
fludrocortisone acetate
×
90 days
×
Clear all
NCT06136650
2026-06-03
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,314 enrolled
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled
NCT06979596
2026-05-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
250 enrolled
NCT06136624
2026-05-05
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,310 enrolled